G protein coupled receptors (GPCRs) constitute the most important drug target classes (Schroder et al., 2010) ,accounting for ~40% of current drugs on the market and are involved in various physiological processes (Rozenfeld and Devi, 2010) . Drug development efforts have focused on this molecular class, as these receptors are located on the cell surface making them easier to target for modulation of cellular activities. According to a recent market analysis by Insight Pharma Reports (Rubenstein, 2008) , GPCRs are targeted for approximately one-third of approved drugs and for hundreds of drugs currently in development.
for GPCRs include platforms for the study of receptor internalization.
Currently, the increasing number of diverse small molecules is being generated through combinatorial chemistry (Pinilla et al., 2003) , and extensive genomic efforts have identifi ednumerous novel GPCR targets. Therefore, the use of highthroughput assays with good sensitivity and specifi city is necessary for high throughput screening campaign (Burbaum and Sigal, 1997) . Especially, for drug discovery research based on GPCR targets, the challenge is how to look for potential drug candidates using a predefi ned compound library.
In this review, a wide array of high-throughput tools for GPCR research are described, and their use for the development of diverse GPCR assessment platforms needed to study 
RECEPTOR-LIGAND INTERACTION

Radioactivity based detection
There are numerous methods to detect receptor-ligand interactions by means of radioactivity. As GPCR scientists are trying to fi nd molecules that inhibit or modulate the action of a ligand on a receptor and thus infl uence the activity of the receptor itself, examining the binding of ligand to a receptor has been the classic means used to study the structure/activity relationship. Thousands of radiolabeled ligands containing 3 H, 125 I, and 14 C are available from PerkinElmer, Inc. The advantages of radiolabeled ligands are versatility, minimum size variation comparing to the original ligands, and cost-effectiveness, however, the use of those ligands are limited because of their intrinsic half-life and the fact that global environmental issues concerning radioactive materials are becoming more sensitive.
In classic binding assays, membrane preparations containing GPCRs of interest are incubated with radiolabeled ligands in the presence of test compounds to assess the chemical's ability to disrupt receptor-ligand interactions in a heterogeneous mode. However, scintillation proximity assays (SPAs) can avoid washing steps needed to remove unbound ligands prior to reading, and provide a homogeneous assay (Wu and Liu, 2005; Glickman et al., 2008) . SPAs uses scintillation beads that can be read on conventional scintillation counters and are suitable for the detection of various isotopes including 3 H, 125 I, 33 P, and 14 C. In addition to the ligand and assay characteristics, membrane preparations for target GPCRs can be secured by in-house development or can be supplied from vendors such as PerkinElmer Life Science, Multi span, Chan Test, and Caliper Life Sciences.
Fluorescence based detection
To overcome numerous limitations related to health and waste disposal in the use of radioactivity based experiments, a growing interest in alternative, nonradioactive technologies (Liu et al., 1998) has become more evident. One traditional fl uorescence application for receptor-ligand binding is the fl uorescence polarization (FP) based approach (Gagne et al., 2002) . Although the FP based approaches are still applied to various enzyme activity assessments, their use in GPCR research is not as wide-spread because of the limited signal to noise ratio. However, the FP assay itself is a very simple, homogeneous, and cost-effective platform.
Fluorescent ligands have been used for decades and offer several advantages over traditional radioligand binding techniques (McGrath et al., 1996) . The use of fl uorescent ligands is steadily growing within the pharmacological community and other disciplines (Daly and McGrath, 2003) , although such ligands have multiple drawbacks including a large fl uorescent background of reagents, which decreases the assay window with plastics and biological samples, leading to reduceddynamic range and sensitivity of fl uorescent tags. Recently, lanthanide labels were introduced and a new caliber of fl uorescence applications was made possible. One of major benefi ts of lanthanide labels is that the long lifetime of the excited state allows the specifi c signal from lanthanide to be temporally separated from the non-specifi c signal , and this phenomenon enables the time resolved fl uorescence (TRF) detection. Recent reports (Inglese et al., 1998; Gao et al., 2004; Handl et al., 2004 Lee et al., 2006) have described the use of lanthanide labeled ligands in a traditional competitive binding assay format, and those ligands are similar to the radiolabeled ligands in potency and effi cacy .Several dissociation-enhanced lanthanide fl uorescent immunoassays (DELFIAs) are now available.
Current developments in TRF applications include the time resolved fl uorescence resonance energy transfer (TR-FRET) technology. To construct a homogeneous assay, TR-FRET employs a second acceptor component to emit a light when the lanthanide labeled ligand is bound to its receptor. The lanthanide chelate excite (LANCE) TR-FRET uses alexa647 labeled lectins or biotinylated lectins in combination with allophycocyanin labeled streptavidin (Hemmila, 1999; Jansson et al., 1999; Branchek et al., 2000) . Most recently, Tag-lite TM , a homogeneous assay technology based on TR-FRET, was announced as a versatile platform technology for the study of receptor-ligand interactions (Maurel et al., 2004) . This assay employs cells genetically modifi ed to express GPCRs that are coupled to a small suicide enzyme (SNAP tag). In the presence of an appropriate fl uorescent substrate, an enzyme covalently conjugates part of its substrate onto itself, providing a way to label GPCR. To detect ligand binding, the labeled cells are incubated with a ligand that is labeled with another fl uorophore, and if there is an interaction with a receptor-ligand, the receptor produces a FRET signal in a time resolved mode.
RECEPTOR-FUNCTIONAL RESPONSES
Measurements of cAMP and IP 3 (IP 1 )
After a receptor-ligand interaction, ligands are bound to their specifi c receptors, and a series of intracellular events are started based on the types of receptor coupled G proteins involved. Those second messengers include cAMP, inositol triphosphate (IP 3 ), and calcium released from intracellular storage. Ligand binding analyses conducted in membrane based assays don't always directly translate to the functions of live cells, and most GPCR assays focus on downstream signaling events, especially those involving second messengers. Some radioactivity based assays are available for this purpose. Additionally, the enzyme-linked immunosorbent assay (ELISA) has been widely employed to detect cAMP. The ELISA method, while reliable and accessible by any laboratory, is heterogeneous and involves a washing step, making it slow and not cost-effective. Recently, amplifi ed luminescent proximity homogeneous assay (ALPHA) technology was introduced as substitute for various ELISA methodologies to improve the assay quality and throughput.
For the measurements of cAMP and IP 3 /IP 1 , recent developments include LANCE (TR-FRET), the β-lactamase reporter assay (FRET), fl uorescence polarization, and homogeneous time resolved fl uorescence (HTRF) based detection. Unlike ELISA methods, these assays are homogeneous, can be performed using a high-throughput format and allow for scale-up or miniaturization, thereby reducing assay development time DOI: 10.4062/biomolther.2011.19.1.001 and costs. Especially, several metabolites in the inositol phosphate cascade have extremely short half-lives, making them diffi cult to accurately quantify. IP 1 , a downstream metabolite of IP 3 , accumulates in cells following Gq receptor activation and is stable in the presence of LiCl, making it a reasonable readout of receptor activation. Also, cAMP can be detected with the live cell luminescent assays by fusing a cAMP binding domain from human protein kinase A to the wild type N-and C-termini of fi refl y luciferase, with new termini created in the larger N-terminal domain (Fan et al., 2008) .
Most recently, enzyme fragment complementation (EFC) technology was introduced as a robust and reliable tool for the assay of biochemical components. EFC is a homogeneous, non-radioactive detection technology based on two genetically engineered β-galactosidase (β-gal) fragments: a large protein fragment (enzyme acceptor, EA), and a small peptide fragment (enzyme donor, ED). Separately, the β-gal fragments are inactive, but in solution, they rapidly recombine to form the active β-gal enzyme that hydrolyzes substrate, producing an easily detectable chemiluminescent or fl uorescent signal. Using this technology, cAMP (luminescence detection) and IP 3 (FP) have been investigated in various biological systems (Sanger et al., 2009; Chen et al., 2010; Eapen et al., 2010; Hampton and Kinnaird, 2010) .
Measurement of intracellular calcium
The central role of Ca 2+ in intracellular signaling makes it a very attractive reporter for the process of drug discovery. Many of the most interesting target classes for the pharmaceutical industry, such as GPCRs, ion channels, and transporters, trigger a Ca 2+ mobilization upon activation (Rink, 1990) . Determination of the activity of targets by measurement of increased intracellular Ca 2+ concentration is now a very common approach, and the development of more sensitive technologies for the measurement of Ca 2+ concentration has long been a matter of interest. The fi rst Ca 2+ mobilization assays were developed using fl uorescence intensity produced by formation of a complex with Ca 2+ , but their use for HTS was limited until the development of the fl uorometric imaging plate reader (FLIPR). Although the use of fl uorescent probes in a homogeneous no-wash format has become very common in HTS, its use is complicated by the inherent fl uorescence of dye loaded cells and interference by the compounds themselves.
Photoproteins have been used to more effectively sense intracellular Ca 2+ concentrations and overcome current limitations of fl uorescence applications (Hedley et al., 1996; Stables et al., 1997; Dupriez et al., 2002; Le Poul et al., 2002; Bovolenta et al., 2007) . The most commonly studied photoproteins are aequorin, isolated from Aequorea victoria, and obelin, isolated from Obelia longissima. Upon calcium binding, the photoprotein oxidizes coelenterazine into colenteramide, with the production of CO 2 and the emission of luminescentlight. Aequorin assays have been validated for many GPCRs and some Ca 2+ channels, and the results obtained are comparable to those obtained with the use of fl uorescent dyes (Maeda et al., 1996) .
Measurements of β-arrestin and extracellular signal regulated kinase (ERK)
The arrestins constitute a family of proteins that are capable of interacting with GPCRs following their activation by agonists and subsequent phosphorylation by G protein coupled receptor kinases (GRKs) (Perry and Lefkowitz, 2002) . Arrestin binding, recognized by both the GRK phosphorylation site and the agonist-activated conformation of receptors (Luttrell and Lefkowitz, 2002) , leads to uncoupling of the receptor from its cognate G protein causing desensitization of G protein signaling via downstream second messenger molecules (Lohse et al., 1990; Perry and Lefkowitz, 2002; Gainetdinov et al., 2004; Lefkowitz, 2004) . Using this theoretical background, a β-arrestin-based assay can rule out false positive hits from a calcium or cAMP primary screen, or validate second messenger hits as an alternative, non-G-protein mediated signaling pathway.
The assay monitors GPCR activity by detecting the interaction of arrestin with the activated GPCR using EFC (Zhao et al., 2008; McGuinness et al., 2009) . In this system, the β-galactosidase (β-gal) enzyme is split into two inactive fragments. The larger portion of β-gal, termed EA for enzyme acceptor, is fused to the C-terminus of β-arrestin. The smaller, 4 kDa complementing fragment of β-gal, the ProLink tag, is expressed as a fusion to the C-terminus of the GPCR of interest. Upon activation, the interaction of β-arrestin and the GPCR forces the interaction of ProLink and EA, resulting in complementation of the two fragments of β-gal and the formation of a functional enzyme capable of hydrolyzing substrate and generating a chemiluminescent signal.
Other assay platforms use the protease tagged arrestin and a non-native transcription factor fused to the C-terminus of the GPCR. As the recruited protease tagged arrestin cleaves the transcription factor by its fused protease site, the transcription factor directly regulates transcription of a β-lactamase reporter construct, which is measured upon addition of the substrate by FRET. Furthermore, by attaching a fl uorescent label to β-arrestin (Oakley et al., 2002) , the location of the receptorarrestin complex can be monitored during receptor activation by high content analysis (HCA).
Upon stimulation of GPCRs by their ligands, receptors activate effectors such as adenylate cyclase and phospholipase C, which infl uence intracellular concentrations of second messengers,and also mediate the phosphorylation of extracellular signal regulated kinase (ERK1/2). GPCRs have also been shown to mediate ERK1/2 activation in a G protein-independent, but β-arrestin dependent manner (Lin et al., 1999; Luttrell and Lefkowitz, 2002; Shenoy and Lefkowitz, 2003) . Based upon this background, measurements of phosphorylated ERK by TR-FRET and ALPHA can be deployed as a secondary screening platform.
RECEPTOR-RECEPTOR INTERACTION
GPCRs can interact with each other at the plasma membrane to form homodimeric and heterodimeric complexes that can profoundly impact GPCR pharmacology and signaling Ferre et al., 2010) . Compounds that specifi cally target GPCR heterodimers have the potential to achieve higher specifi city with reduced side effects, defi ne new drug targets, or behave as modulators of GPCR activity in specifi c tissues (Rozenfeld and Devi, 2010) . As a result, there is considerable interest in the design of drugs that target GPCR heterodimers (Bhushan et al., 2004; Daniels et al., 2005; Waldhoer et al., 2005; Xie et al., 2005) .
The EFC based GPCR dimerization system is designed to identify novel compounds that act through GPCR heterodimer www.biomolther.org pairs. In this system, arrestin is fused to the larger portion of β-gal, termed enzyme acceptor of EA, and the smaller, 42 amino acid ProLink tag is localized to one of the GPCR targets of interest. Using these arrestin clones as the starting material, a second untagged GPCR receptor can be stably introduced into the cell line and the effects of the untagged GPCR on the ProLink-tagged GPCR can be measured using chemiluminescence detection reagents (Vidi and Watts, 2009 ). In addition to the EFC technology, the bioluminescence resonance energy transfer (BRET) has been applied for research on receptorreceptor interactions (Hamdan et al., 2006) . One candidate interacting GPCR is fused to a luminescent energy donor, such as Renilla luciferase, and the other to a fl uorescent energy acceptor, such the green or yellow fl uorescent protein (GFP/ YFP), and the two are then coexpressed in the same cells. If the two GPCRs interact, their close proximity allows nonradiative energy transfer (BRET) between the luciferase and the GFP/YFP. BRET does not occur if the two GPCRs are separated by more than 100 Å, making the technique ideal for monitoring receptor-receptor interactions in biological systems.
Most recently, a methodology combining TR-FRET with SNAP technology to quantitatively analyze receptor-receptor interactions at the surface of living cells was investigated (Albizu et al., 2010; Maurel et al., 2008) . A newer version of the Tag-lite platform, with a dual tag (SNAP/CLIP tag), is under development to label with two different substrates. Some of the known receptor-receptor interactions in various GPCR targets are listed in Table 2 .
RECEPTOR INTERNALIZATION
GPCRs are thought to become separated from their cognate G proteins and effectors as they start to internalize. Endocytosed receptors either traffi c to lysosomes for degradation or follow a recycling route. In this way, receptor internalization controls receptor density at the cell surface and serves as a mechanism to attenuate signal duration and strength, although it has been known that endocytic traffi cking does not necessarily lead to signal termination (Calebiro et al., 2010; Jalink and Moolenaar, 2010) . Therefore, GPCR platforms have been developed that are not based on specifi c signaling mechanisms to confi rm and expand effects of an agonist or antagonist.
Most recently, an internalization assay based on a reduction of the HTRF was introduced. This Tag-lite TM assay is G protein and β-arrestin independent, and applicable to perform GPCR kinetic internalization assays. The detection reagent used is non-permeable and contains the HTRF acceptors. When the receptor is at the cell surface, HTRF occurs between the SNAP-Lumi4-Tb labeled GPCR and the detection reagent in the medium causing the FRET ratio to be decreased. When the receptor is internalized, energy transfer can no longer occur, causing an increased FRET ratio.In the presence of a specifi c agonist, the GPCR desensitization induces receptor internalization which causes low dynamic FRET to have a high ratio signal.
Another assay was designed using low-affi nity EFC technology, which relies on protein proximity to yield complementation of two partial fragments of β-galactosidase. One enzyme fragment is localized exclusively to the surface of cellular endosomes and the complementing enzyme fragment is fused to the GPCR of interest. Stimulation of the target receptor results in internalization of the receptor and traffi cking to cellular endosomes. This action forces the complementation of the two enzyme fragments, resulting in an increase of enzyme activity that is easily measured using chemiluminescent detection.
CONCLUSION AND FUTURE PERSPECTIVES
GPCRs are transmembrane receptors that transmit signals from the outside of a cell to the inside. These receptors are involved in every aspect of human physiology, including sleep regulation, blood pressure, mood, food intake, perception of pain, control of cancer growth, and immune response (Lefkowitz, 2004) . With their complex signaling network pathways, GPCRs constitute one of the most important target (Cheng et al., 2007; Tamayama et al., 2005 ) (Hirono et al., 2001; Kamikubo et al., 2007; Rives et al., 2009; Tabata et al., 2004 ) (Ciruela et al., 2001; Toms and Roberts, 1999 ) (Cabello et al., 2009; Ferre et al., 2002; Ferre et al., 2010; Soriano et al., 2009) classes studied in the pharmaceutical industry. Currently, a wide array of high-throughput tools is available for research on GPCRs, and these tools are applicable for detecting the receptor-ligand interaction, receptor driven functional response, receptor-receptor interaction and receptor internalization. The main focus in these research areas includes development of non-radiometric technologies in the homogeneous assay format, permitting the newly developed assay to be applied in a HTS campaign for drug discovery efforts. As one of important emerging technologies, label-free platforms such as EPIC (Dodgson et al., 2009; Schroder et al., 2010) , an optical-based biosensor, and Cellkey (Verdonk et al., 2006; Peters et al., 2007) , an electrical impedance-based biosensor, are receiving attention because there is no need to modify target cells. These label-free platforms may provide a broader cellular concept of GPCR functionality. For example, EPIC uses changes in the refractive index of light on a sensor surface to detect subtle fl uctuations in mass distribution such as those caused by cell movement or vesicle traffi cking. However, the resulting label-free data information is complex and diffi cult to analyze, therefore, established in vitro assays should be integrated to deconvolute the holistic information.
In the same sense, multiple readouts in the mechanistic studies of GPCRs are receiving more attention because of their complicated signaling mechanisms and intracellular interactions. Recently, a possible fl aw in a luminescence reporter assay was reported (Auld et al., 2009) . In this case, compounds could directly affect the reporter, leading to nonspecifi c, but highly reproducible assay signal modulation. Therefore, the consideration of counter-screening is recommended in most uses of the assay platform.
In addition to luminescence technologies, homogeneous fl uorescence methodologies provide highly sensitive and robust technology for the detection of molecular interactions during the HTS stage of drug development. New fl uorescent ligands and photoproteins have been developed to address the need for cell based models that can reduce gaps between in vitro and in vivo studies conducted for drug discovery programs. However, because of the technology barrier presented by intellectual property issues, such as licensing costs, the use of those technologies is very limited in the academic sector comparing to the pharmaceutical industries. Fortunately, some of those assay kits are provided in the form of growth arrested frozen cells, so that one can conveniently use commercial kits without the need for assay validation or culture maintenance.
In conclusion, the availability of research tools for GPCR studies has been very limited compared to other biochemical targets. Recently, various platform technologies for research on GPCRs have been developed and efforts are being made to more closely mimic physiological conditions and obtain a higher screening throughput. Assay technology is rapidly advancing and the combination of probe chemistry, optical instruments, and GPCR biology will provide us with many new technologies to apply in the future.
